ASCO Annual Meeting | Conference

Partners of HPV-Positive Oropharyngeal Cancer Patients Not at Increased Risk of HPV Infection or Oral Cancer

June 2nd 2013

Patients with human papilloma virus–positive oropharyngeal cancer and their spouses may find some reassurance in a study that found that partners are no more likely to be infected by HPV than the general population.

Maintenance Therapy With Pazopanib Delays Relapse of Advanced Ovarian Cancer

June 2nd 2013

An oral targeted drug already approved by the FDA for the treatment of kidney cancer and soft tissue sarcoma has been found to extend disease-free survival in women with advanced ovarian cancer.

Dr. Tewari on Bevacizumab in Advanced Cervical Cancer

June 2nd 2013

Krishnansu S. Tewari, MD, from the University of California Irvine in Orange, California, discusses the effectiveness of bevacizumab in relapsed and metastatic cervical cancer.

Cetuximab OS Results Top Bevacizumab in mCRC

June 2nd 2013

Frontline cetuximab plus FOLFIRI chemotherapy improved overall survival by 3.7 months versus bevacizumab plus FOLFIRI in patients with KRAS wild-type metastatic colorectal cancer.

Nivolumab Delivers Enduring Benefits in Advanced Melanoma

June 2nd 2013

Nivolumab has demonstrated an overall objective response rate of 31% with a median duration of two years in patients with advanced melanoma.

Dr. Sznol Describes Nivolumab in Advanced Melanoma

June 2nd 2013

Mario Sznol, MD, from the Yale Cancer Center, discusses the long-term follow-up results from an expanded phase I study investigating the anti-PD-1 drug nivolumab in patients with advanced melanoma.

Dr. D'Souza on Spouses of HPV-Positive Patients

June 1st 2013

Gypsyamber D‘Souza, PhD, MPH, MS, from Johns Hopkins University, discusses the prevalence of oral HPV infections in the spouses of patients with HPV-positive oropharyngeal cancer.

Dr. du Bois on Pazopanib in Advanced Ovarian Cancer

June 1st 2013

Andreas du Bois, MD, from Kliniken Essen Mitte in Essen, Germany, discusses a phase III trial exploring the effectiveness of treatment with maintenance pazopanib for patients with advanced ovarian cancer.

Dr. Carvajal Describes MEK Inhibition in Uveal Melanoma

June 1st 2013

Richard D. Carvajal, MD, a medical oncologist at Memorial Sloan-Kettering Cancer Center, describes the success of MEK inhibition in patients with advanced uveal melanoma using the agent selumetinib.

ASCO Highlights Put Variety in Spotlight

June 1st 2013

New data on emerging immunotherapies and fresh findings about established agents are likely to dominate clinical and marketplace news from this year's Annual Meeting of the ASCO, according to industry analysts.

Dr. O'Shaughnessy on Everolimus in Breast Cancer

June 1st 2013

Joyce A. O'Shaughnessy, MD, the Co-Director of Breast Cancer Research at the Baylor Charles A. Sammons Cancer Center, describes potentially practice changing findings from the BOLERO-3 trial.

ASCO Opens 49th Annual Meeting Urging More Federal Funding for Research

June 1st 2013

The American Society of Clinical Oncology kicked off its 49th Annual Meeting with leaders urging all stakeholders in cancer care to vigorously oppose cuts to vital US biomedical research funding.

Dr. Pazdur on Breakthrough Designation Requirements

May 31st 2013

Richard Pazdur, MD, from the FDA's Center for Drug Evaluation and Research, emphasizes the importance of adequate data supporting proposals to the FDA for breakthrough therapy designations.

Four Head and Neck Cancer Highlights From ASCO 2013

May 21st 2013

This article summarizes 4 abstracts that will be discussed at the 49th Annual ASCO Meeting, focused on the treatment of patients with head and neck cancer.

Combining Ipilimumab and Nivolumab Shows Promise in Advanced Melanoma

May 16th 2013

Combining the checkpoint antibodies ipilimumab and nivolumab led to deep tumor regression in approximately one-third of patients with advanced melanoma.

High Levels of Cardiovascular Fitness Reduces the Risk of Developing and Dying From Cancer

May 15th 2013

Men with a high level of cardiovascular fitness at middle age had a reduced risk of developing and dying from lung and colorectal cancer later in life.

New PI3K-delta Inhibitor Prolongs Survival in Chronic Lymphocytic Leukemia

May 15th 2013

The novel selective PI3K-delta inhibitor idelalisib produced rapid and prolonged tumor shrinkage in patients with relapsed or refractory chronic lymphocytic leukemia who received the drug as a monotherapy.

Adjuvant Surveillance Effective in Early-Stage Seminoma

May 15th 2013

Active surveillance following radical orchiectomy is an effective treatment strategy for men with stage I seminoma.

Follow-Up Scans Do Little to Detect Relapse of Diffuse Large B-Cell Lymphoma

May 15th 2013

Routine follow-up imaging is of limited value in determining whether patients with diffuse large B-cell lymphoma have experienced a relapse of their disease.

In Treating Locally Advanced NSCLC, More Radiotherapy Is Not Better

May 15th 2013

Radiotherapy at a higher-than-standard dose is harmful to patients with locally advanced non-small cell lung cancer who are also getting concurrent and consolidation chemotherapy.

x